Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Fulcrum Therapeutics Slides As Insider Purchases Lose Another US$362k
Oppenheimer Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $14
RBC Capital Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Fulcrum Therapeutics Analyst Ratings
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Cautious Hold Rating on Fulcrum Therapeutics Amid Uncertain Prospects and Strategic Shifts
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript Summary
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript
Fulcrum Therapeutics GAAP EPS of -$0.35 Beats by $0.05
Fulcrum Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Fulcrum Therapeutics Inc: Cash Runway Into at Least 2027
Express News | Fulcrum Therapeutics Q3 Operating Income USD -25.126 Million
Express News | Fulcrum Therapeutics Q3 Net Income USD -21.696 Million
Earnings Scheduled For November 13, 2024
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
Fulcrum Therapeutics's Earnings Outlook
Fulcrum Launches AI-Powered Field Platform
Earnings Preview: FULC to Report Financial Results Pre-market on November 13
$Fulcrum Therapeutics(FULC.US)$ is scheduled to release its financial results pre-market on November 13 ET. Earnings PreviewAnalysts estimate $Fulcrum Therapeutics(FULC.US)$ to post revenue of USD0
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 A.m. ET